Fujifilm Holdings Corp.

What Fujifilm Holdings Corp. does

Fujifilm Holdings Corporation (TSE: 4901) is a publicly traded Japanese conglomerate operating through three reportable segments — Healthcare, Electronics, and Business Innovation — with a global workforce of over 70,000 employees. Founded in 1934, the company has executed a multi-decade pivot from its legacy photographic film business into healthcare imaging, biopharmaceutical contract manufacturing, and advanced electronic materials; the Healthcare segment now generates more than half of consolidated operating income. Its Healthcare business supplies medical imaging equipment (endoscopes, X-ray systems, ultrasound devices) under a razor-and-blade model that pairs equipment sales with recurring consumables and service contracts, while its CDMO operations (FUJIFILM Biotechnologies, FUJIFILM Cellular Dynamics) deliver end-to-end biologics and cell therapy manufacturing services from large-scale facilities in Holly Springs, North Carolina ($3.2B investment, 800+ employees) and Teesside, UK (£400M / $545M expansion, 19,000L bioreactor capacity).

The technology stack spans proprietary imaging platforms, bioprocess innovations (continuous electroporation gene delivery, Oceo Rover automated hydration, ShunzymeX protease-based purification, inline Raman sensing co-developed with Horiba), semiconductor packaging materials under the ZEMATES line (polyimide, PBO dielectric films, thermal management materials, CMP slurries, and a newly developed PFAS-free PBO formulation with imec), and AI-enabled X-ray imaging used for early cancer detection and lesion segmentation. Revenue is generated across at least four primary verticals — Healthcare Providers, Pharmaceutical Companies, Semiconductor Manufacturers, and Commercial Printers — via a mix of direct enterprise field sales, strategic channel partnerships (notably KARL STORZ for GI endoscopes), and participation in major industry events (BIO, ECTC, DCAT Week). Adjacent revenue streams include digital printing (industrial inkjet, offset inks, direct-to-package), pressure measurement films (Round Prescale), and renewable energy procurement (Blevins Solar VPPA offsetting 100% of US/Canada electricity usage). The 2026 CDMO Leadership Award for Most Innovative CDMO (Biologics) and the Red Dot "Best of the Best" design award for the GFX100RF camera validate recent product and innovation execution.

Name

Fujifilm Holdings Corp.

Legal name

FUJIFILM Holdings Corporation

Website

https://fujifilmholdings.com

Company type

Public

Founded year

1934

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Fujifilm Holdings Corp. is a publicly traded Japanese conglomerate supplying medical imaging equipment, biopharmaceutical CDMO services, semiconductor packaging materials, and digital printing solutions to healthcare providers, pharmaceutical companies, semiconductor manufacturers, and commercial printers globally.

Ownership category

akta.pro rank

Product category

Medical Imaging Equipment

NAICS

Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Medical Equipment and Supplies Manufacturing (33911)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Gene Therapy Vector Manufacturing & CDMO Services (HLAAACAJ)

akta.pro secondary industries

Viral Vector Manufacturing Services (AAV, lentiviral, adenoviral) (HLAAAKAD), mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA) (HLAGAGAC), GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification) (HLAGAGAL)

Keywords

• Medical imaging equipment
• Biopharmaceutical CDMO services
• Semiconductor packaging materials
• Digital printing solutions
• Healthcare consumables

Headquarters

HQ city

Minato

HQ country

Japan

HQ region

Asia

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Infrastructure, Operations, Supply Chain, Personnel, Marketing or Sales

Revenue model

1. Healthcare Equipment with Recurring Consumables and Services: Razor-and-blade model pairing equipment sales (endoscopes, X-ray systems, ultrasound devices) with recurring consumables and service revenue
2. Biopharmaceutical CDMO Services: Contract development and manufacturing organization services for biologics, including cell culture manufacturing and single-use bioreactor capacity
3. Electronic Materials: Semiconductor packaging materials including polyimide, PBO films, thermal management materials, and CMP slurries
4. Digital Printing Solutions: Digital printing services including inkjet technology for commercial, packaging, and textile applications

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

FUJIFILM Holdings Corporation develops, manufactures, and sells medical imaging equipment (endoscopes, X-ray systems, ultrasound devices) along with recurring consumables and services. The company also operates biopharmaceutical contract development and manufacturing (CDMO) services through FUJIFILM Biotechnologies, produces semiconductor packaging materials under the ZEMATES product line, and offers digital printing solutions for commercial, packaging, and textile applications. Healthcare is the largest operating segment, generating over half of the company's operating income.

Product overview

Fujifilm Holdings Corp. is a diversified Japanese conglomerate operating through three core segments—Healthcare, Electronics, and Business Innovation—with over 70,000 employees globally. The company has transformed from a film manufacturer into a diversified healthcare imaging and advanced materials company, with the Healthcare segment generating over half of operating income. The product portfolio includes biopharmaceutical manufacturing technologies (continuous electroporation gene delivery systems, Oceo Rover Automated Hydration System, ShunzymeX™ platform), medical imaging equipment (endoscopes, X-ray systems, ultrasound devices), semiconductor packaging materials (ZEMATES product line including PFAS-free PBO, polyimide, thermal management materials, CMP slurries), industrial printing solutions (direct-to-package printing, offset inks), pressure measurement films (Round Prescale), and iPSC products through FUJIFILM Cellular Dynamics. Major manufacturing facilities include a $3.2 billion cell culture biomanufacturing plant in Holly Springs, NC and a £400 million expanded CDMO facility in Teesside, UK—the UK's largest single-use CDMO facility.

Differentiator

Problem solved

Functional benefit

Products and services

• Oceo Rover Automated Hydration System
• Continuous Electroporation Gene Delivery System
• Inline Raman High-Sensitivity Measurement System
• ShunzymeX Technology Platform
• ZEMATES Product Line
• Round Prescale
• Healthcare Imaging Solutions
• FUJIFILM Cellular Dynamics iPSC Products
• Direct-to-Package Printing Solutions
• Offset Inks
• Flexible GI Endoscopes

Quantifiable outcome

• Approximately 10% higher antibody yields compared to conventional UV-Vis spectrometry methods
• +2 more outcomes

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature7 records

Partnerships

Five partnerships are on record, tiered strategic and core.

• Tokyo Gas and TGESstrategicStrategic or Co-development Partner · 25 June 2026Agreement to supply city gas linked to biomethane produced overseas, supporting Fujifilm's sustainability initiatives.
• Horiba Ltd.coreTechnology or Integration · 16 June 2026Fujifilm Corporation and Horiba jointly developed an inline Raman high-sensitivity measurement system for real-time monitoring of component concentrations during biopharmaceutical manufacturing. The technology integrates Horiba's Raman spectrometry with Fujifilm's single-use probes and proprietary measurement algorithms, achieving approximately 10% higher antibody yields.
• imeccoreStrategic or Co-development Partner · 26 May 2026Joint research with imec to develop PFAS-free PBO materials for semiconductor packaging, leveraging Fujifilm's expertise in molecular design and formulation.
• Geronimo PowercoreOthers · 21 April 2026Virtual Power Purchase Agreement with Geronimo Power for renewable energy certificates from the Blevins Solar & Storage Project in Falls County, Texas. The 125 MW solar project (2,300 acres) generates 300,000 MWh annually, offsetting 100% of Fujifilm's group companies' electricity usage in the United States and Canada.
• KARL STORZcoreChannel Partner/ Reseller/ Distributor · 1 August 2024Partnership between KARL STORZ and Fujifilm Healthcare Americas to promote flexible GI endoscopes and OR integration solutions, combining KARL STORZ's endoscopy expertise with Fujifilm's imaging capabilities.

Scale indicators12 records

Recent moves9 records

Expansion highlights5 records

Direct peers

• Samsung Biologics: Major Korean CDMO rapidly scaling large-scale mammalian cell culture capacity for monoclonal antibodies and biologics, competing head-to-head with FUJIFILM Biotechnologies for pharma outsourcing contracts and pursuing similar gene therapy and mRNA capabilities.
• Catalent, Inc. Leading global CDMO providing biologics development, fill-finish, and cell therapy manufacturing services that directly overlap with FUJIFILM Biotechnologies' biopharmaceutical manufacturing and gene therapy offerings.
• Konica Minolta, Inc. Closest historical analog as a Japanese conglomerate pivoting from photographic film to healthcare (digital imaging, healthcare IT) and industrial printing—sharing Fujifilm's diversification arc and Japanese enterprise dynamics.
• Lonza Group AG: World's largest biopharmaceutical CDMO, offering mammalian cell culture, microbial fermentation, and biologics manufacturing services that directly compete with FUJIFILM Biotechnologies across gene therapy, mRNA, and traditional biologics programs.

Broad incumbents

• Siemens Healthineers: Global medical imaging leader with a more diversified portfolio than Fujifilm, including CT, MRI, and AI-enabled X-ray imaging where it holds roughly 3% share, beating Fujifilm's 2% in AI-enabled imaging.
• 3M Company: Diversified global conglomerate with overlapping exposure in healthcare/medical products, advanced electronic materials, and industrial specialty segments—sharing Fujifilm's multi-vertical conglomerate structure and capital allocation challenges.
• GE HealthCare: Dominant medical imaging incumbent with a broad portfolio spanning CT, MRI, ultrasound, and X-ray systems that competes directly with Fujifilm's imaging equipment business while also layering AI-enabled diagnostics.
• Canon Inc. Diversified Japanese imaging and printing conglomerate with medical imaging systems, semiconductor lithography equipment, and commercial printing operations that directly overlap with multiple Fujifilm segments.
• Philips (Royal Philips): Major medical imaging player with a strong presence in ultrasound, X-ray, and AI-enabled diagnostics, competing with Fujifilm's imaging portfolio while also pursuing broader healthcare technology and connected care solutions.

Emerging players

• JSR Corporation: Japanese specialty chemicals and materials company expanding aggressively into life sciences and bioprocessing (including CDMO capabilities via its acquisition of Crown Bioscience and MBL), directly overlapping with FUJIFILM Biotechnologies' CDMO ambitions.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/fujifilmholdings

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Fujifilm Holdings Corp.